idea-003 · business case

Who pays, from which budget, how much, and 2-4 commercial routes to first revenue — every figure below traces to a copied claim or a declared assumption, and the routes are laid out unranked. Choosing a commercial strategy is a Tier 3 act, so this page presents options and stops.

Commutable patient-matrix reference material panel for validating tumor-informed ctDNA MRD assays (clinical QC material) — business case

Intended use: Quality control material — intended for use by molecular laboratories to monitor the analytical performance (analytical sensitivity at defined low tumor fractions, specificity, and inter-run precision) of tumor-informed circulating tumor DNA minimal residual disease assays, during assay validation and in routine run-by-run quality control. Not a calibrator, and not for use in establishing or interpreting an individual patient result.

Who pays

One cheque, written by a laboratory out of its own budget. There is no payer leg for the product: nobody bills a payer for a control material, and the product has no code claim 55unconfirmed claim 14unconfirmed. P2 clinical QC material at launch changes who inside the laboratory the product is sold to, not that.

Writes the cheque: two buyers, one per SKU. The daily-use single-level control is bought by CLIA (Clinical Laboratory Improvement Amendments) laboratories that report patient tumor-informed MRD (molecular residual disease) results and run a control on every run claim 151unconfirmed claim 177unconfirmed. The **multi-level validation panel** is bought by those laboratories and by assay developers that report no patient results (IVD (in vitro diagnostic) kit makers, pharma and CRO assay groups, academic labs) claim 150unconfirmed claim 154unconfirmed. Whether either buyer can order it as a bench consumable rather than through capital procurement is claim 26unconfirmed; under P2 clinical QC material at launch the daily control is the easier case for that and the panel is not.
Out of which budget line: the laboratory's QC (quality control)-consumables operating budget, which is funded by what the laboratory is paid for the test the control monitors. That is the only checked money in this chain, and it belongs to the customer: Medicare pays $3,590.00 per 0340U service on the CLFS (clinical laboratory fee schedule) claim 71verified, on 25,746 Medicare FFS (fee-for-service) services in CY2024 claim 68verified, with 0356U and 0422U at $1,800.00 and $1,943.21 claim 74verified on 4,481 and 243 services claim 75verified. Four active MolDX MRD articles list 0340U claim 72verified claim 73verified, which is existence, not coverage; that L38779 (a Medicare local coverage determination number) gives criteria-gated coverage is claim 136unconfirmed. None of this is the product's revenue, and none of it is a market size.
Against which comparator: four things a laboratory does today.
- It builds its own contrived controls claim 21unconfirmed.
- It dilutes an incumbent buffer-format material into its own plasma. The Seraseq ctDNA (circulating tumour DNA) MRD Panel Mix is four 200 ng vials at 0%, 0.5%, 0.05% and 0.005% tumor fraction in TE buffer claim 111unconfirmed, at $1,919.59 on a distributor web page claim 117unconfirmed, and diluting its 0.05% level costs roughly $80 per run claim 177unconfirmed.
- It buys an RUO (research use only) plasma-format control. AcroMetrix Multi-Analyte ctDNA Plasma Control A shows $490.00 on one storefront and $1,617.00 on another for the same vial claim 123unconfirmed claim 124unconfirmed.
- It buys a listed 866.5910 control. Illumina lists oncology DNA/RNA controls under SCU (subcutaneous) claim 132unconfirmed, and a third party lists BCR-ABL1 monitoring controls under QIG claim 155unconfirmed. Neither listing has been read by any connector.
Stops buying instead: nothing is forced off the bench. CLIA requires the laboratory to run control material every day for molecular amplification claim 7verified but names no material, source or traceability for either the controls or the LoD study claim 76verified claim 77verified. What P2 clinical QC material at launch would displace is a particular material, whether in-house, a diluted buffer mix or an RUO plasma control. Whether it does is claim 177unconfirmed for the control and claim 153unconfirmed for the panel.

The payer-side pull is unread, and it is the one that would matter. If MolDX's technical assessment required LoD to be shown on known-VAF (variant allele frequency) material, a payer would be pulling this product without paying for it. That L38779 requires a technical assessment is claim 126unconfirmed. That its analytical-validity criteria require known-VAF material without naming a source is claim 137unconfirmed. That the TA FAQs permit purchased material is claim 165unconfirmed. The BLOODPAC contrived-sample functional characterization requirement is claim 164unconfirmed. Four documents, none read by a connector. Until one is read, the only verified demand driver is CLIA's, and it points at no supplier.

Reimbursement path

Six questions, each with its own evidence position and one basis. No score, no tier, no composite. The rubric already treats Factor 2 as having no referent for this product, and nothing below gives it one. What the section adds is where the absence sits.

#	Question	Finding	Basis
2a	Coding route — Cat I / Cat III / unlisted / HCPCS (Healthcare Common Procedure Coding System) II / none	None, and none is sought. The product is an operating input bought by a laboratory, not a service or item billed to a payer; there is no code to put to `hcpcs`, and "none is achievable" is a forward-looking negative no database settles claim 14unconfirmed. P2 clinical QC material at launch does not change this: a Class II (FDA device class II) 866.5910 listing is a device status, not a billing status claim 131verified. The only codes in the chain are the customers' PLA codes, such as 0340U claim 71verified	claim 55unconfirmed
2b	Payment adequacy — does the rate clear a stated cost floor	No payer rate exists to test; the analogous test is the laboratory's purchase price against unit cost, and it is unrun. The price is a willingness-to-pay claim, $1,500-$3,000 per panel and $400-$900 per vial claim 149unconfirmed. The unit-cost build-up behind the cost floor does not exist claim 140unconfirmed. Whether about $875,000 a year at planning volumes and low-end prices exceeds fully loaded COGS (cost of goods sold) plus the recurring 866.5910 obligations has no cost side at all	claim 178unconfirmed
2c	Practice-expense headroom — does the PE portion cover the device	There is no practice-expense portion anywhere in this chain, by construction. The only payment in it is the customer's CLFS national limitation amount, a single national rate per test, $3,590.00 for 0340U claim 71verified. The CLFS carries no PE split, and `rvu 0340U` returns refuted because the code is not on the PFS (physician fee schedule) at all. The control's cost is recovered, if at all, out of that one per-test rate	claim 71verified
2d	Site of care & bundling — office/facility differential, DRG or APC packaging	Independent-laboratory setting only; no facility claim for a DRG or APC to package into. The CMS (Centers for Medicare & Medicaid Services) release carries one national row for 0340U, office/non-facility, 25,746 services, and no facility row claim 68verified. The product's own position is the bundled one anyway: its cost sits inside the laboratory's per-test payment with no add-on, which is the half resting on claim 55unconfirmed. `apc 0340U` and `drg` return unconfirmed on missing caches, which is a tooling gap and not a finding	claim 68verified
2e	Coverage — has any payer agreed to pay for this indication	No payer covers a control material, and none is expected to. Coverage exists only one step away, for the customer's test: four active MolDX MRD articles list 0340U claim 72verified, but existence is not a stance, and criteria-gated coverage under L38779 is claim 136unconfirmed. What matters commercially is whether that coverage requires material like this, and that is claim 137unconfirmed	claim 55unconfirmed
2f	Ex-US pathway — DE NUB/G-DRG, UK NICE (National Institute for Health and Care Excellence)/OPCS-4	Permanently unconfirmed, and additionally without referent. `launch_jurisdiction:` is US; no connector reaches a non-US payment system, and a control material has no payer route in any system the question names	— none

Pillars on verified claims: 2/6 · on assumptions: 0 · queued as research: 0

The other four: 2a, 2b and 2e rest on unconfirmed claims, and 2f on nothing. Read the split before the six. Both verified pillars (2c and 2d) are verified facts about the customer's payment: it is a CLFS national rate with no practice-expense split, billed in the independent-laboratory setting. Neither is about this product. Both point the same way: the payment structure has no line in it for a control material. They make the absence better evidenced. They do not make anything green. The rows that describe the product itself (2a, 2e) rest on a forward-looking negative claim 55unconfirmed that no database can settle.

Three distinctions kept apart deliberately:

A code existing is not payment, and payment is not coverage. Here all three exist for the customer's test (its PLA code, its CLFS rate claim 71verified, four MolDX articles claim 72verified) and none exists for the product. Quoting the customer's three as if they were the product's is the collapse this section exists to prevent.
A packaged code pays nothing extra, and the laboratory is in the same position. A control is an input to a per-test payment the laboratory already receives, and no separate line recovers its cost. This is why the product's economics are a purchase decision inside the laboratory's margin, not a reimbursement question.
2f is a permanent unconfirmed. Nothing in the repo reaches a non-US payment system.

Verdicts recorded where a check was run cold this pass and came back unusable:

python3 -m connectors cpt 0340U → unverifiable — "CPT descriptors are AMA-licensed and cannot be scraped or reproduced verbatim (phase2-spec.md Section 3). The code NUMBER is not barred". No descriptor is reproduced on this page. What 0340U describes stays at claim 8unconfirmed.
python3 -m connectors hcpcs 0340U → unconfirmed — "0340U is a CPT (Level I) code, not HCPCS Level II, so the Level II file cannot say whether it exists." The product has no code of its own to put to hcpcs.
python3 -m connectors rvu 0340U → refuted — "No code 0340U in the cached CMS Physician Fee Schedule RVU file. It is not priced under the PFS". This supports 2c's reading and travels as claim 71verified, not as a new basis.
python3 -m connectors apc 0340U → unconfirmed — "No local cache at data/opps_addendum_b.csv". drg is keyed on a DRG number and has nothing to look up for a laboratory consumable. Both are tooling gaps, not findings.
python3 -m connectors payment 0340U, procedures 0340U, coverage 0340U → verified, re-run cold, matching claim 71verified, claim 68verified and claim 72verified. Re-running a lookup does not make a new basis; the figures travel as those claims.

The money model

The size is decomposed in the market model, built today against the same P2 clinical QC material at launch shape. It is not rebuilt here. Its coverage line reads legs on verified claims 0/7. Every leg below is the candidate's own number, copied from a claim the Verifier looked at and could not check. This table quotes the legs this case needs and adds the cost side, which the market model does not carry.

Line	Figure	Backing
Line A: US organisations buying a multi-level validation panel	8-60	claim 150unconfirmed — floor from eight companies in one MolDX article claim 125unconfirmed, ceiling from the Generator's 30-60 laboratories claim 12unconfirmed
Line A: validation panels per organisation per year	3-20	claim 150unconfirmed — the Verifier records this input as having no source
Line A: realized net price per panel	$1,500-$3,000	claim 149unconfirmed — willingness to pay; `adoption` refuses it by design
Line B: US laboratories running a daily run-by-run control on patient MRD testing	30-60	claim 151unconfirmed — a subset of Line A's population, yet its floor of 30 sits above Line A's floor of 8; the market model records the inconsistency claim 125unconfirmed
Line B: daily-control vials per laboratory per year	250 (a point, not a range)	claim 151unconfirmed — the once-a-day CLIA minimum claim 7verified read as a consumption rate. The market model names it the leg most likely to be wrong, in either direction
Line B: realized net price per daily-control vial	$400-$900	claim 149unconfirmed — bounded above the lab-diluted incumbent route at roughly $80 per run claim 177unconfirmed, which is ceiling pressure the range does not reflect
Reachable share for one new supplier by year 3 (both lines)	10%-30%	claim 151unconfirmed — the 10% floor from claim 47unconfirmed; the 30% is the Commercial chair's
Serviceable pool, one supplier, year 3 (the market model's arithmetic over the legs above)	$303,600-$5,130,000 a year	claim 150unconfirmed × claim 151unconfirmed × claim 149unconfirmed — Line B carries 79%-99% of the addressable pool at either end, so the daily control, not the panel, is what this is a business in
Commercial's planning point inside that band	about $875,000 a year (50 panels and 2,000 vials at $1,500 and $400)	claim 178unconfirmed — arithmetic checked by the Verifier; inputs unconfirmed
Fully loaded unit cost, panel	not stated anywhere; the only test is whether it falls below the $1,919.59 incumbent web price	claim 140unconfirmed
Recurring annual cost of the 866.5910 obligations (QMS (quality management system), registration and listing, UDI (unique device identifier), complaint and MDR (medical device report) handling)	not stated anywhere; obligations verified, cost unpriced	claim 159verified for the obligations; claim 178unconfirmed for whether revenue covers them
Gross margin	not stated anywhere	claim 49unconfirmed — the P0 the original shape-era form; claim 178unconfirmed is its P2 clinical QC material at launch numeric test

Read the largest number as a statement about the file, not the market. The $5.13M ceiling is seven unconfirmed legs multiplied together claim 150unconfirmed claim 151unconfirmed claim 149unconfirmed, and its span is narrow only because leg 5 is a point claim 151unconfirmed. The one check the market model could run against it goes through the customers' Medicare FFS test revenue of about $101M claim 68verified claim 71verified claim 74verified claim 75verified. That figure is never multiplied into this model and floors nothing in it. Folded through the file's own top-down QC-spend share of 0.5%-1.5% claim 11unconfirmed, it reconciles with the band only if all-payer MRD test revenue is several times the Medicare FFS book and laboratories buy most of their QC material rather than make it claim 76verified claim 77verified. The top-down volume that the P0 the original shape case started from is refuted claim 10refuted, and the P0 the original shape case's rate line claim 9unconfirmed is superseded in substance by claim 71verified. That is why neither appears in the table.

What P2 clinical QC material at launch did to the money, in one line: it kept the daily-control line, which is most of the pool claim 151unconfirmed, and added a fixed cost layer before the first sale claim 159verified. A fixed layer over a pool this size is why the cost rows above matter more than the price rows. Operations calls P2 clinical QC material at launch "a fixed-cost product" at planning volumes, and that reading is claim 140unconfirmed until priced.

Both refusing connectors were run cold this pass against P2 clinical QC material at launch-shaped claims, and the verdicts go on the page:

python3 -m connectors market "Annual US revenue available by year 3 to one new supplier of a multi-level validation panel and a daily run-by-run clinical quality control material for tumor-informed ctDNA MRD assays, sold under 21 CFR 866.5910, is between 0.3 and 5.1 million USD" → unverifiable — "Market-size claim (…) has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."
python3 -m connectors adoption "US laboratories running tumor-informed ctDNA MRD assays on patient specimens will buy a listed 866.5910 daily run-by-run control at 400-900 USD per vial in place of in-house contrived controls" → unverifiable — "No free, authoritative, machine-queryable source answers that — it needs primary research (interviews, survey, published preference study)… Do NOT substitute a model's own estimate of stakeholder behaviour: a synthetic stakeholder opinion is a fabricated claim."

The adoption connector's suggested rescope (coverage, procedures) was followed and is recorded in the reimbursement section above. It returns the customer's test, which is the closest checkable proxy and is not this product's demand claim 68verified.

Path to first revenue

First dollar comes from: a CLIA laboratory reporting patient tumor-informed MRD results that buys the daily-use single-level control as its run-by-run external control claim 177unconfirmed, or an assay developer that buys the multi-level panel for a validation study claim 150unconfirmed. It is a sale of a listed device to a laboratory, never a reimbursement event claim 55unconfirmed.
What must exist first, each attributed:
- The 866.5910 exemption must apply, not just exist. SCU is verified as Class II and 510(k) (premarket notification)-exempt claim 131verified. Whether the 866.9(c)(1) neoplastic-disease limb withdraws it is claim 52unconfirmed, and the 866.9(a) different-use limb is claim 156unconfirmed. Whether a native-plasma matrix is a "reasonably foreseeable characteristic" of the type is claim 157unconfirmed. Only a 513(g) response settles these, and if it goes the other way a 510(k) comes before revenue claim 52unconfirmed.
- A documented 21 CFR (Title 21 of the Code of Federal Regulations) 820 quality system complying with ISO (International Organization for Standardization) 13485, with design controls, UDI and complaint reporting, before first distribution claim 159verified. This is the layer P2 clinical QC material at launch added and that the P0 the original shape budget never carried.
- The special-control study set: matrix effects, extraction, per-variant value assignment, multi-lot stability, reproducibility at 3 or more sites. Nobody has read the 2007 guidance it comes from claim 158unconfirmed.
- A pilot lot whose sub-0.1% levels carry a derived value with at most 35% relative expanded uncertainty claim 134unconfirmed, cross-checked by aggregate sequencing claim 169unconfirmed, then three lots on independent pools within 20% of nominal claim 170unconfirmed.
- A daily control whose label states its expected molecule count and zero-copy probability, at a level where an in-control run holds at least one mutant molecule with probability of 95% or more claim 160unconfirmed. The 0.03% design point is claim 166unconfirmed.
- Plasma: every donation tested under 21 CFR 610.40 claim 61verified, a supplier for a pooled lot of at least 10 L claim 172unconfirmed, and consent terms that permit commercial use claim 148unconfirmed. The spike cell lines must carry redistribution terms claim 176unconfirmed.
Calendar to first dollar: the only stated figure is 9-15 months claim 50unconfirmed, and it was written for the RUO shape, with no quality system and no production-lot series in its path. Under P2 clinical QC material at launch the calendar is [assumption A1 In vitro diagnostic products properly…]. If the 513(g) goes against claim 52unconfirmed, a 510(k) review sits on top of it.
Capital to first dollar: the only stated figure is a low-single-digit-million budget claim 20unconfirmed. It prices a wet lab, a dPCR (digital polymerase chain reaction) platform, plasma and ISO 17034-oriented documentation, and states "no premarket submission". It carries neither the 21 CFR 820 layer claim 159verified nor a production volume claim 58verified. Whether P2 clinical QC material at launch's fixed layer fits inside it is [assumption A2 FDA guidance "Distribution of In Vitro…]. ISO 17034 is elective under P2 clinical QC material at launch rather than a launch precondition, and whether buyers would pay for it is claim 129unconfirmed.

Routes

Four, laid out and not ranked. Choosing a commercial strategy is a Tier 3 act, so this section presents options and stops. Routes A, B and C all sell the P2 clinical QC material at launch product under 866.5910 and share one exposure, which is stated once here rather than three times: a 513(g) reading that withdraws the exemption claim 52unconfirmed puts a 510(k) in front of all three. That changes their calendars, not their economics, and it is not the kill condition of any one of them. Route D does not carry that exposure, and it carries the RUO exposure that P2 clinical QC material at launch was made to remove instead.

Route A — P2 clinical QC material at launch as written: own quality system, both SKUs, direct to MRD laboratories

Build the 21 CFR 820 quality system in-house, list both SKUs under SCU, and sell direct.

Requires: the exemption to apply claim 52unconfirmed claim 156unconfirmed; a quality system with design controls before first distribution claim 159verified; the special-control study set claim 158unconfirmed; a pilot lot that meets its uncertainty budget claim 134unconfirmed; laboratories that switch their run-by-run control to it claim 177unconfirmed; and a direct technical-sales motion without a distributor claim 28unconfirmed.
Costs: the standing-start calendar [assumption A1 In vitro diagnostic products properly…], the one-time fixed layer [assumption A2 FDA guidance "Distribution of In Vitro…] on top of the RUO-era budget claim 20unconfirmed, and the recurring 866.5910 obligations every year after claim 178unconfirmed.
Killed by: a fully loaded cost build-up showing that at Commercial's planning volumes and the low end of its prices, revenue does not cover COGS plus the recurring 866.5910 cost claim 178unconfirmed. A route that owns its whole fixed layer is the one this finding ends outright.

Route B — P2 clinical QC material at launch product, made and released inside an existing 866.5910 establishment

Same product, same listing and same customers. The quality system belongs to a contract manufacturer that already lists devices under SCU, NZB or QIG.

Requires: an establishment that offers third-party manufacture of nucleic-acid QC materials claim 171unconfirmed; transfer of the dilution-chain value assignment into its quality system claim 134unconfirmed; the same exemption reading as Route A claim 52unconfirmed; and the same switching laboratories claim 177unconfirmed.
Costs: a per-vial toll price that has to sit below the price the vial sells for [assumption A3 Enforcement risk claim]; a single-source manufacturing dependency the file does not currently carry claim 59verified; and the pilot-lot development spend, which stays with idea-003 claim 20unconfirmed.
Killed by: no registered 866.5910 establishment offering contract manufacture of nucleic-acid QC material to third parties claim 171unconfirmed. Without one, Route B collapses into Route A.

Route C — License the value-assignment method to an incumbent that already runs ISO 13485

Sell the differentiator, not the vials. The licensee's existing quality system carries the P2 clinical QC material at launch layer, and idea-003 carries the method and the pilot-lot evidence.

Requires: an incumbent willing to license rather than build claim 51unconfirmed; a method with something to license, meaning patentability of the P1 derived-value bottom levels dilution-chain combination claim 175unconfirmed and no blocking incumbent claim claim 174unconfirmed; and a pilot lot that demonstrates the budget claim 134unconfirmed claim 169unconfirmed.
Costs: the pilot-lot build before any licensee would look claim 20unconfirmed, and giving up the direct unit revenue of the serviceable pool claim 178unconfirmed for terms no claim in the file describes. How often these incumbents have in fact bought a third-party method is [assumption A4 A quality control material whose entire…].
Killed by: none of the named incumbents being willing to license or acquire the method rather than build it in-house claim 51unconfirmed.

Route D — Development-phase-only RUO panel, no daily control

The shape the front end keeps on the table and has not taken. Delete performance monitoring, sell the multi-level panel only to developers that report no patient results, and exclude validation support by contract.

Requires: enough non-CLIA-reporting MRD developers to sell to claim 154unconfirmed; a sales motion that stays out of clinical laboratories, because the RUO exemption is conditioned on the research phase and on not representing the product as an effective IVD claim 1unconfirmed claim 3unconfirmed; and the same pilot lot as every other route claim 134unconfirmed.
Costs: the RUO-era budget and calendar, which were written for this shape claim 20unconfirmed claim 50unconfirmed, with no 21 CFR 820 layer. It also gives up Line B, the daily control, which carries most of the serviceable pool claim 151unconfirmed.
Killed by: fewer than ten US organisations developing tumor-informed MRD assays without reporting patient results from a CLIA laboratory claim 154unconfirmed. That leaves the route almost no customers it may lawfully court.

Assumption register

Every assumption cited above, with what would settle it and who could run it. These were appended to the candidate on 2026-09-26 as unverified claims 179-182 via append_commercial_claims.py, before this file was written. The P0 the original shape case's A1 In vitro diagnostic products properly…-A5 21 CFR 866.5910's generic type are claims 47-51, already on the candidate and tagged unconfirmed. They are cited above as claims and not re-registered.

#	Assumption	Falsifier	Owner
A1 In vitro diagnostic products properly…	From a standing start, first commercial distribution of idea-003 as a 21 CFR 866.5910 device takes longer than the 9-15 months claim 50unconfirmed states for the RUO-era shape, because a documented ISO 13485 / 21 CFR 820 quality system with design controls, UDI and complaint handling must precede distribution (claim 159verified), and the P2 clinical QC material at launch plan puts three production lots on independent pools in the path (claim 170unconfirmed). claim 179unconfirmed	A critical-path plan with named vendor lead times: a QMS consultant or eQMS quote with an implementation calendar, a plasma-pool supply lead time (claim 172unconfirmed), pilot-lot and three-lot durations, and the REQ-0096 Under 21 CFR 866.5910 as a 510 answer on whether special-control data must precede distribution	Operations & NPI (new product introduction), with Regulatory for the REQ-0096 Under 21 CFR 866.5910 as a 510 half
A2 FDA guidance "Distribution of In Vitro…	The one-time cost of idea-003's P2 clinical QC material at launch fixed layer (the 21 CFR 820 / ISO 13485 quality system with design controls, UDI and complaint and MDR handling, the special-control design-verification study set, and three production lots) fits inside the low-single-digit-million first-revenue budget that claim 20unconfirmed states without that layer. claim 180unconfirmed	The REQ-0083 Produce the cost-of-goods build-up your… bottom-up build with the fixed layer itemized: QMS set-up quote, design-verification study costs per claim 158unconfirmed's list, three lots' plasma, testing and value-assignment cost, compared line by line with claim 20unconfirmed	Operations & NPI
A3 Enforcement risk claim	At least one FDA (US Food and Drug Administration)-registered establishment listing a device under 866.5910 (SCU, NZB or QIG) would quote to manufacture and release idea-003's daily-use control under its own quality system at a per-vial toll price below $400, the low end of claim 149unconfirmed's range. claim 181unconfirmed	An RFQ to the establishments behind the registration numbers on the NZB, QIG and SCU classification records (claim 171unconfirmed lists them), asking for a written toll-manufacture quote at 2,000 vials a year	Operations & NPI, with business development
A4 A quality control material whose entire…	Since 2016, at least one of LGC Clinical Diagnostics/SeraCare, Revvity/Horizon Discovery, Twist Bioscience or Thermo Fisher Scientific has publicly announced in-licensing, or acquiring as a single asset, a nucleic-acid reference-material or QC-material production method developed by a third party. This is the revealed-behaviour twin of claim 51unconfirmed. claim 182unconfirmed	A search of the four companies' press-release archives and SEC filings (8-K, 10-K business sections) for licence or asset-purchase announcements naming a reference-material or QC-material method, recording the counterparty and the stage of the asset at signing	45_research

Where this case outruns the file

Every figure and every step with no verified claim behind it, gathered in one place. These are the work items.

All seven size legs. Organisations, panels per organisation, panel price, laboratories, vials per laboratory, vial price and reachable share are the candidate's own unconfirmed numbers (claims 149-151, 47). The serviceable band of $0.30M-$5.13M and the $875K planning point are arithmetic over them. The market model has five research rows filed against these legs; leg 5 (vials per laboratory per year) is the one most able to move the band.
The whole cost side. No unit cost (claim 140unconfirmed), no recurring 866.5910 compliance cost (claim 178unconfirmed), no gross margin (claim 49unconfirmed), no P2 clinical QC material at launch calendar (A1 In vitro diagnostic products properly…) and no P2 clinical QC material at launch capital figure (A2 FDA guidance "Distribution of In Vitro…) exists anywhere in the file. Under P2 clinical QC material at launch the product is fixed-cost at planning volumes, so this is the side that decides the business, and it is entirely empty.
The regulatory placement the three P2 clinical QC material at launch routes share. The exemption is verified to exist (claim 131verified) and not to apply (claims 52, 156, 157). One 513(g) settles it, and it is a human spend decision.
The payer-side demand pull. Whether L38779's technical assessment requires known-VAF material for LoD (claim 137unconfirmed), and what the TA FAQs and BLOODPAC say (claims 165, 164). Four documents, all readable by a human, none by a connector. If none of them requires the material, the only demand driver left is CLIA's, which names no supplier (claims 76, 77).
Switching. Whether one laboratory in ten would move its run-by-run control to this product at $400-$900 a vial, against roughly $80 a run for a lab-diluted incumbent mix (claim 177unconfirmed). This is class 3 and adoption refuses it permanently. Its nearest revealed-behaviour twin, the share of molecular oncology labs using commercial rather than in-house controls today, is already a filed market-model research row.
Routes B and C's counterparties. A contract manufacturer's toll price (A3 Enforcement risk claim) and an incumbent's appetite for a licence (claim 51unconfirmed; its twin A4 A quality control material whose entire…). The file names no counterparty for either.
The cheapest falsifier on this page is A4 A quality control material whose entire…, a desk search of four companies' press releases and SEC filings. It reads Route C's counterparty behaviour without asking anyone anything. A3 Enforcement risk claim's RFQ is next cheapest, and it is the only item here that prices a unit.

Words on this page26 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md

21 CFR: Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k): premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
Class II: FDA device class II — moderate-risk devices, usually cleared by 510(k)
CLFS: clinical laboratory fee schedule — the Medicare price list for laboratory tests
CLIA: Clinical Laboratory Improvement Amendments — the US rules a clinical laboratory must meet to report test results on patients
CMS: Centers for Medicare & Medicaid Services — the US agency that runs Medicare, and so decides what Medicare pays for
COGS: cost of goods sold — what it costs to make one unit
ctDNA: circulating tumour DNA — fragments of a tumour's DNA found in the blood
dPCR: digital polymerase chain reaction — a laboratory method that counts individual DNA molecules
FDA: US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
FFS: fee-for-service — the traditional form of Medicare that pays per item or service
HCPCS: Healthcare Common Procedure Coding System — the US billing codes for equipment, supplies and some services; a code is how a payer recognises what to pay for
ISO: International Organization for Standardization — the body whose numbered standards devices and laboratories are tested against
IVD: in vitro diagnostic — a test run on a sample taken from the body rather than on the body
L#####: a Medicare local coverage determination number — the public id of one local coverage rule; the letter L and five digits
MDR: medical device report — a report to the FDA of a device problem
MRD: molecular residual disease — cancer left behind after treatment, too little to see on a scan, detected through DNA in the blood
NICE: National Institute for Health and Care Excellence — the English body whose guidelines say what the NHS should use
NPI: new product introduction — taking a design into manufacture: tooling, suppliers, first production
PFS: physician fee schedule — the Medicare price list for what clinicians do
QC: quality control — the samples and checks a laboratory runs to prove its test is still working
QMS: quality management system — the documented processes a manufacturer must run to be allowed to sell a device
RUO: research use only — a labelling status that keeps a product out of patient diagnosis; no FDA review, no clinical claims
SCU: subcutaneous — under the skin
UDI: unique device identifier — the barcode-style id every marketed device carries
VAF: variant allele frequency — what share of the DNA fragments at one position carry the tumour's mutation; the lower it is, the harder the test

Generated from knowledge-base/commercial/idea-003.md by engine/scripts/build_review.py on 2026-10-04. This page is a view — edit the source file and rebuild, never edit here.